Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral phenoxodiol dose-escalation study in refractory prostatic adenocarcinoma
ACTRN12605000512628Phase 2Active, not recruiting
- Sponsor
- MEI Pharma
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of idronoxil in prostate adenocarcinoma and refractory prostatic adenocarcinoma (4 arms), sponsored by MEI Pharma. Primary endpoints: Pharmacokinetic profile of oral phenoxodiol and Safety and tolerability of oral phenoxodiol. Started Oct 2002; status: active, not recruiting.
02
Drugs
idronoxil
03
Conditions
prostate adenocarcinomarefractory prostatic adenocarcinoma
Beyond the preview
Go deeper on ACTRN12605000512628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000512628.